Rabeprazole: A second-generation proton pump inhibitor in the treatment of acid-related disease

Expert Review of Gastroenterology and Hepatology

Volumn 2, Issue 4, 2008, Pages 509-522

  Pallotta, Stefano ^a   Pace, Fabio ^b   Marelli, Silvia ^c  

^a UNIVERSITY OF MILAN   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

^c Janssen Cilag SpA Italia   (Italy)

Author keywords

Acid related disorder; Atypical symptoms; Gastroesophageal reflux disease; Helicobacter pylori eradication; Peptic ulcer disease; Proton pump; Rabeprazole; Zollinger Ellison syndrome

Indexed keywords

ACETYLSALICYLIC ACID; ALFENCE; AMOXICILLIN; ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; CLARITHROMYCIN; ESOMEPRAZOLE; LANSOPRAZOLE; LEVOFLOXACIN; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; OMEPRAZOLE; PANTOPRAZOLE; PLACEBO; PROTON PUMP INHIBITOR; RABEPRAZOLE; RANITIDINE; TACROLIMUS; TINIDAZOLE; UNCLASSIFIED DRUG;

ARTICLE; BARRETT ESOPHAGUS; CLINICAL TRIAL; DOSAGE SCHEDULE COMPARISON; DRUG BIOAVAILABILITY; DRUG COST; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG INDICATION; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG MEGADOSE; DRUG METABOLISM; DRUG POTENTIATION; DRUG RESPONSE; DRUG SAFETY; DRUG STRUCTURE; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; DUODENUM ULCER; ENDOSCOPIC THERAPY; ERADICATION THERAPY; GASTROESOPHAGEAL REFLUX; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; LOW DRUG DOSE; MAINTENANCE THERAPY; NAUSEA; PEPTIC ULCER BLEEDING; REPEATED DRUG DOSE; SINGLE DRUG DOSE; STOMACH MUCOSA INJURY; STOMACH ULCER; STRUCTURE ANALYSIS; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT; ZOLLINGER ELLISON SYNDROME;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; BARRETT ESOPHAGUS; GASTROESOPHAGEAL REFLUX; HUMANS; PROTON PUMP INHIBITORS; STOMACH ULCER; ZOLLINGER-ELLISON SYNDROME;

EID: 55649087082     PISSN: 17474124     EISSN: None     Source Type: Journal    
DOI: 10.1586/17474124.2.4.509     Document Type: Article

References (104)

1. Carswell CI, Goa KL. Rabeprazole: an update of its use in acid related disorders. Drugs 61(15), 2327-2356 (2001).
2. Ofman JJ, Dorn GH, Fennerty MB, Fass R. The clinical and economic impact of competing management strategies for gastro-oesophageal reflux disease. Aliment. Pharmacol. Ther. 16(2), 261-273 (2002).
3. Remak E, Brown RE, Yuen C, Robinson A. Cost-effectiveness comparison of current proton-pump inhibitors to treat gastro-oesophageal reflux disease in the UK. Curr. Med. Res. Opin. 21(10), 1505-1517 (2005).
4. Dubois D. Hughes DA, Bodger K, Bytzer P. Economic analysis of on-demand maintenance therapy with proton pump inhibitors in patients with non-erosive reflux disease. Pharmacoeconomics 23(10), 1031-1041 (2005).
5. Kivioja A, Linnosmaa I, Vehvilainen A, Vohlonen I. Cost-minimization analysis of treatment of gastroesophageal reflux disease. Implications of varying holding time on conclusions. Eur. J. Pharm. Sci. 21(2-3), 171-178 (2004).
6. Hall J, Dodd S, Durkin M, Sloan SA. Impact of proton pump inhibitor utilization patterns on gastroesophageal reflux disease-related costs. Manag. Care 11(Suppl. 7), 14-18 (2002).
7. Roche VF. The chemically elegant proton pump inhibitors. Am. J. Pharm. Educ. 70(5), 101 (2006).
8. Kromer W, Kruger U, Huber R, Hartmann M, Steinijans VW. Differences in pH-dependent activation rates of substituted benzimidazoles and biological in vitro correlates. Pharmacology 56(2), 57-70 (1998).
9. Sachs G. Improving on PPI-based therapy of GORD. Eur. J. Gastroenterol. Hepatol. 13(Suppl. 1), $35-$41 (2001).
10. Tomiyama Y, Morii M, Takeguchi N. Specific proton pump inhibitors E3810 and lansoprazole affect the recovery process of gastric secretion in rats differently. Biochem. Pharmacol. 48 (11), 2049-2055 (1994).
11. Besancon M, Simon A, Sachs G, Shin JM. Sites of reaction of the gastric H, K-ATPase with extracytoplasmic thiol reagents. J. Biol. Chem. 272(36), 22438-22446 (1997).
12. Fock KM, Ang TL, Bee LC, Lee EJD. Proton pump inhibitors. Do differences in pharmacokinetics translate into differences in clinical outcomes ? Clin. Pharmacokinet. 47(1), 1-6 (2008).
13. Swan SK, Hoyumpa AM, Merrit GJ. Review article: the pharmacokinetics of rabeprazole in health and disease. Aliment. Pharmacol. Ther. 13(3), 11-17 (1999).
14. Fuhr U, Jetter A. Rabeprazole: pharmacokinetics and pharmacokinetic drug interactions. Pharmazie 57, 595-601 (2002).
15. James L, Walson P, Lomax K, Kao R, Varughese S, Reyes J; on behalf of the study 119 pediatric trial investigators. Pharmacokinetics and tolerability of rabeprazole sodium in subjects aged 12 to 16 years with gastroesophageal reflux disease: an open-label, single- and multiple-dose study. Clin. Ther. 29, 2082-2092 (2007).
16. Lim PW, Goh KL, Wong BC. CYP2C19 genotype and the PPIs - focus on rabeprazole. J. Gastroenterol. Hepatol. 20, S22-S28 (2005).
17. McColl KE, Kennerley P. Proton pump inhibitors - differences emerge in hepatic metabolism. Dig. Liver Dis. 34(7), 461-467 (2002).
18. Horn J. Review article: understanding the pharmacodynamic and pharmacokinetic differences between proton pump inhibitors - focus on pKa and metabolism. Aliment. Pharmacol. Ther. 2, 340-350 (2006).
19. Adachi K, Katsube T, Kawamura A et al. CYP2C19 genotype status and intragastric pH during dosing with lansoprazole or rabeprazoie. Aliment. Pharmacol. Ther. 13, 1259-1266 (2000).
20. Ariizumi K, Ohara S, Koike T et al. Therapeutic effects of 10 mg once daily rabeprazole administration on reflux esophagitis was not influenced by the CYP2C19 polymorphism. J. Gastroenterol. Hepatol. 21(9), 1428-1434 (2006).
21. Ando T, Kato H, Sugimoto N et al. A comparative study on endoscopic ulcer healing of omeprazole versus rabeprazole with respect to CYP2C19 genotypic differences. Dig. Dis. Sci. 50(9), 1625-1631 (2005).
22. Kawabata H, Habu Y, Tomioka H et al. Effect of different proton pump inhibitors, differences in CYP2C19 genotype and antibiotic resistance on the eradication rate of Helicobacter pylori infection by a 1-week regimen of proton pump inhibotor, amoxicillin and clarithromycin. Aliment. Pharmacol Ther. 17(2), 259-264 (2003).
23. Kuwayama H, Asaka M, Sugiyama T et al. Rabeprazole-based eradication therapy for Helicobacter pylori: a large-scale study in Japan. Aliment. Pharmacol. Ther. 25(9), 1105-1113 (2007).
24. Miura M, Inoue K, Kagaya H et al. Influence of rabeprazole and lansoprazole on the pharmacokinetics of tacrolimus in relation to CYP2C19, CYP3A5 and MDR1 polymorphisms in renal transplant recipients. Biopharm. Drug Dispos. 28(4), 167-175 (2007).
25. Takahashi K, Yano I, Fukuhara Y et al. Distinct effects of omeprazole and rabeprazole on the tacrolimus blood concentration in a kidney transplant recipient. Drug Metab. Pharmacokinet. 22(6), 441-444 (2007).
26. Robinson M, Barone J. Review. article: comparative pharmacodynamic review of rabeprazole- focus on day 1 data. Aliment. Pharmacol. Ther. 2, 315-326 (2006).
27. Pantoflickova D, Dorta G, Ravic M, Jornod P, Blum AL. Acid inhibition on the first day of dosing: comparison of four proton pump inhibitors. Aliment. Pharmacol. Ther. 17, 1507-1514 (2003).
28. Luo JY, Niu CY, Wang XQ, Zhu YL, Gong J. Effect of a single oral dose of rabeprazole on nocturnal acid breakthrough and nocturnal alkaline amplitude. World J. Gastroenterol. 9(11), 2583-2586 (2003).
29. Norris V, Baisley K, Dunn K, Warrington S, Morocutti A. Combined analysis of three crossover clinical pharmacology studies of effects of rabeprazole and esomeprazole on 24-h intragastric pH in healthy volunteers. Aliment. Pharmacol. Ther. 25, 501-510 (2007).
30. Warrington S, Baisley K, Boyce M, Tejura B, Morocutti A, Miller N. Effects of rabeprazole, 20 mg, or esomeprazole, 20 mg, on 24-h intragastric pH and serum gastrin in healthy subjects. Aliment. Pharmacol. Ther. 16, 1301-1307 (2002).
31. Warrington S, Baisley K, Dunn K, Boyce M, Morocutti A. Effects of single doses of rabeprazole 20 mg and esomeprazole 40 mg on 24-h intragastric pH in healthy subjects. Eur. J. Clin. Pharmacol. 62(9), 685-691 (2006).
32. Warrington S, Baisley K, Lee D et al. Pharmacodynamic effects of single doses of rabeprazole 20 mg and pantoprazole 40 mg in patients with GERD and nocturnal heartburn. Aliment. Pharmacol. Ther. 25, 511-517 (2007).
33. Armstrong D, James C, Camacho F et al. Oral rabeprazole vs. intravenous pantoprazole: a comparison of the effect on intragastric pH in healthy subjects. Aliment. Pharmacol. Ther. 25, 185-196 (2006).
34. Bruley Des Varannes S, Gharib H, Bicheler V et al. Effect of low-dose rabeprazole and omeprazole on gastric acidity: results of a double blind, randomized, placebo-controlled, three-way crossover study in healthy subjects. Aliment. Pharmacol. Ther. 20, 899-907 (2004).
35. Shimatani T, Inoue M, Kuroiwa T et al. Acid-suppressive efficacy of a reduced dosage of rabeprazole: comparison of 10 mg twice daily rabeprazole with 20 mg twice daily rabeprazole, 30 mg twice daily lansoprazole, and 20 mg twice daily omeprazole by 24-hr intragastric pH-metry. Dig. Dis. Sci. 50(7), 1202-1206 (2005).
36. Saitoh T, Fukushima Y, Otsuka H et al. Effects of rabeprazole, lansoprazole and omeprazole on intragastric pH in CYP2C19 extensive metabolizers. Aliment. Pharmacol. Ther. 16, 1811-1817 (2002).
37. Shimatani T, Inoue M, Kuroiwa T et al. Acid-suppressive effects of rabeprazole, omeprazole, and lansoprazole at reduced and standard doses: a crossover comparative study in homozygous extensive metabolizers of cytochrome P450 2C 19. Clin. Pharmacol. Ther. 79, 144-152 (2006).
38. de Korwin JD, Ducrotté P, Vallot T. New-generation proton pump inhibitors: progress in the treatment of peptic acid diseases? Presse Med. 33(11), 746-754 (2004).
39. Lee Y, Lin J, Wang H, Chiu H, Wu M. Influence of cyrochrome P450 2C19 genetic polymorphism and dosage of rabeprazole on accuracy of proton-pump inhibitor testing in Chinese patients with gastroesophageal reflux disease. J. Gastroenterol. Hepatol. 22, 1286-1292 (2007).
40. Sloan S. Rabeprazole-based therapy in the management of symptomatic gastroesophageal reflux disease. Am. J. Gastroenterol. 98(Suppl. 3), S49-S55 (2003).
41. Miner P Jr, Orr W, Filippone J, Jokubaitis L, Sloan S. Rabeprazole in nonerosive gastroesophageal reflux disease: a randomized placebo-controlled trial. Am. J. Gastroenterol. 97(6), 1332-1339 (2002).
42. Fock KM, Teo EK, Ang TL, Chua TS, Ng TM, Tan YL. Rabeprazole vs esomeprazole in non-erosive gastro-esophageal reflux disease: a randomized, double-blind study in urban Asia. World J. Gastroenterol. 11(20), 3091-3098 (2005).
43. Jacobson BC, Delemos B, Sun Y, Xiang J, Lococo J, Murphy A. Treatment outcomes with rabeprazole (RAB) 20 mg vs placebo (PBO) in overweight/ obese patients with nonerosive reflux disease (NERD): analysis of two US multicenter trials. Acta of the 108th AGA scientific meeting, Abstract T1220. Gastroenterology 132(4 Suppl. 2), A493 (2007).
44. Thjodlejfsson B, Beker JA, Dekkers C. The European Rabeprazole Study Group. Rabeprazole vs omeprazoie in preventing relapse of erosive or ulcerative gastroesophageal reflux disease: a double blind multicenter European trial. Dig. Dis. Sci. 45(5), 845-853 (2000).
45. Caos A, Moskovitz M, Dayal Y, Perdomo C, Niecestro R, Barth J. Rabeprazole Study Group. Rabeprazole for the prevention of pathologic and symptomatic relapse of erosive or ulcerative gastroesophageal reflux disease. Am. J. Gastroenterol. 95(11), 3081-3088 (2000).
46. Dekkers CP, Baker JA, Thjodleifsson B, Gabryelewicz A, Bell NE, Humphries TJ; The European Rabeprazole Study Group. Double-blind comparison [correction of Double-blind, placebo-controlled comparison] of rabeprazole 20 mg vs. omeprazole 20 mg in the treatment of erosive or ulcerative gastro-oesophageal reflux disease. Aliment. Pharmacol Ther. 13(1), 49-57 (1999).
47. Robinson M, Fitzgerald S, Hegedus R, Murthy A, Jokubaitis L; FAST Trial Investigators. Onset of symptom relief with rabeprazole: a community-based, open-label assessment of patients with erosive oesophagitis. Aliment. Pharmacol. Ther. 16(3), 445-454 (2002).
48. Adachi K, Hashimoto T, Hamamoto N et al. Symptom relief in patients with reflux esophagitis: comparative study of omeprazole, lansoprazole, and rabeprazole, J. Gastroenterol. Hepatol. 18(12), 1392-1398 (2003).
49. Pace F, Annese V, Prada A; Italian Rabeprazole Study Group. Rabeprazole is equivalent to omeprazole in the treatment of erosive gastro-oesophageal reflux disease. A randomised, double-blind, comparative study of rabeprazole and omeprazole 20 mg in acute treatment of reflux, followed by a maintenance open-label, low-dose therapy with rabeprazole. Dig. Liver Dis. 37(10), 741-750 (2005).
50. Bytzer P, Morocutti A, Kennedy P, Ravic M, Miller N; Rose Trial Investigators. Effect of rabeprazole and omeprazole on the onset of gastro-oesophageal reflux disease symptom relief during the first seven days of treatment. Scand. J. Gastroenterol. 41 (10), 1132-1140 (2006).
51. Pilotto A, Franceschi M, Leandro G et al. Comparison of four proton pump inhibitors for the short-term treatment of esophagitis in elderly patients. World J. Gastroenterol. 13(33), 4467-4472 (2007).
52. Miwa H, Sasaki M, Furuta T; ARS Research Group. Efficacy of rabeprazole on heartburn symptom resolution in patients with non-erosive and erosive gastro-oesophageal reflux disease: a multicenter study from Japan. Aliment. Pharmacol. Ther. 26(1), 69-77 (2007).
53. Jacobson BC, Delemos B, Sun Y et al. PPI efficacy in overweight/ obese patients with erosive GERD): rabeprazole (RAB) 20 mg vs Omeprazole (OME) 20 mg. Acta of the 72nd ACG scientific meeting, Abstract 89. Am. J. Gastroenterol. 102(Suppl. 2), S150 (2007).
54. Bytzer P, Blum A, De Herdt D, Dubois D, the Trial Investigators. Six-month trial of on demand rabeprazole 10 mg maintains symptom relief in patients with non-erosive reflux disease. Aliment. Pharmacol Ther. 20, 181-188 (2004).
55. Pace F, Tonini M, Pallotta S, Molteni P, Porto GB. Systematic review: maintenance treatment of gastro-oesophageal reflux disease with proton pump inhibitors taken on demand. Aliment. Pharmacol. Ther. 26, 195-204 (2007).
56. Ponce J, Arguello L, Bastida G, Ponce M, Ortiz V, Garrigues V. On-demand therapy with rabeprazole in nonerosive and erosive gastroesophageal reflux disease in clinical practice: effectiveness, health-related quality of life, and patient satisfaction. Dig. Dis. Sci. 49(6), 931-936 (2004).
57. Bour B, Staub JL, Chousterman M et al. Long-term treatment of gastro-oesophageal reflux disease patients with frequent symptomatic relapses using rabeprazole: on-demand treatment compared with continuous treatment. Aliment. Pharmacol. Ther. 21(7), 805-812 (2005).
58. Cotè GA, Ferriera MR, Rozenberg-Ben-Dror K, Howden CW. Programme of stepping down from twice daily proton pump inhibitor therapy for symptomatic gastro-oesophageal reflux disease associated with a formulary change at a VA medical center. Aliment. Pharmacol. Ther. 25, 709-714 (2007).
59. Birbara C, Breiter J, Thjodleifsson B et al. European Rabeprazole Study Group. A randomized, double-blind trial of the efficacy and safety of 10 or 20 mg rabeprazole compared with 20 mg omeprazole in the maintenance of gastro-oesophageal reflux disease over 5 years. Aliment. Pharmacol. Ther. 17(3), 343-351 (2003).
60. Caos A, Breiter J, Perdomo C, Barth J. Long-term prevention of erosive or ulcerative gastro-oesophageal reflux disease relapse with rabeprazole 10 or 20 mg vs placebo: results of a 5-year study in the United States. Aliment. Pharmacol. Ther. 22(3), 193-202 (2005).
61. Rindi G, Fiocca R, Morocutti A, Jacobs A, Miller N, Thjodleifsson B; European Rabeprazole Study Group. Effects of 5 years of treatment with rabeprazole or omeprazole on the gastric mucosa. Eur. J. Gastroenterol. Hepatol. 17(5), 559-566 (2005).
62. Morgan DG, O'Mahony MF, O'Mahony WF; RAB-GRD-3002 Study Group. Mainteinance treatment of gastroesophageal reflux disease: an evaluation of continuous and on-demand therapy with rabeprazole 20 mg. Can. J. Gastroenterol. 21(12), 820-826 (2007).
63. Barth J, Perdomo C, Sloan S. Rabeprazole maintains GERD healing in patients with Barrett's esophagus (abstract and poster). Am. J. Gastroenterol. 94, 2579 (1999).
64. Wani S, Sampliner RE, Weston AP et al. Lack of predictors of normalization of oesophageal acid exposure in Barrett's oesophagus. Aliment. Pharmacol. Ther. 22(7), 627-633 (2005).
65. Gerson LB, Shetler K, Triadafilopoulos G. Control of intra-oesophageal and intra-gastric pH with proton pump inhibitors in patients with Barrett's oesophagus. Dig. Liver Dis. 37(9), 651-658 (2005).
66. Sarela AI, Hick DG, Verbeke CS, Casey JF, Guillou PJ, Clark GW. Persistent acid and bile reflux in asymptomatic patients with Barrett esophagus receiving proton pump inhibitor therapy. Arch. Surg. 139(5), 547-551 (2004).
67. Johnston MH, Eastone JA, Horwhat JD, Cartledge J, Mathews JS, Foggy JR. Cryoablation of Barrett's esophagus: a pilot study. Gastrointest. Endosc. 62(6), 842-848 (2005).
68. Oda K, Iwakiri R, Hara M et al. Dysphagia associated with gastroesophageal reflux disease is improved by proton pump inhibitor. Dig. Dis. Sci. 50(10), 1921-1926 (2005).
69. Dickman R, Emmons S, Cui H et al. The effect of a therapeutic trial of high-dose rabeprazole on symptom response of patients with non-cardiac chest pain: a randomized, double-blind, placebo-controlled, crossover trial. Aliment. Pharmacol. Ther. 22(6), 547-555 (2005).
70. Swiarkowski M, Budzynski J, Klopocka M et al. Suppression of gastric acid production may improve the course of angina pectoris and the results of treadmill stress test in patients with coronary artery disease. Med. Sci. Monit. 10(9), CR524-CR529 (2004).
71. Orr WC, Goodrich S, Robert J. The effect of acid suppression on sleep patterns and sleep-related gastro-oesophageal reflux. Aliment. Pharmacol. Ther. 21(2), 103-108 (2005).
72. Shaheen NJ, Madanick RD, Alattar M et al. Gastroesophageal reflux disease as an etiology of sleep disturbance in subjects with insomnia and minimal reflux symptoms: a pilot study of prevalence and response to therapy. Dig. Dis. Sci. 23(4), 134-138 (2007).
73. Tsugeno H, Mizuno M, Fujiki S et al. A proton-pump inhibitor, rabeprazole, improves ventilatory function in patients with asthma associated with gastroesophageal reflux. Scand. J. Gastroenterol. 38(5), 456-461 (2003).
74. Peterson K, Fang J, Canale C, Ryujin D, Young D, Samuelson W. The role of gastroesophageal reflux (GER) in exercise triggered asthma. Acta of the 108th AGA scientific meeting, Abstract 913. Gastroenterology 132(4 Suppl. 2), A140 (2007).
75. Friedenberg FK, Simmons K, Palit A. Rabeprazole sodium 20 mg BID improves symptoms in patients with chronic persistent asthma. Acre of the 72nd ACG scientific meeting, Abstract 89. Am. J. Gastroenterol. 102(Suppl. 2), S121-S122 (2007).
76. Klopocka M, Sinkiewicz A, Budzyuski J, Pulkowski G, Swiatkowski M. Improvement in clinical course and laryngeal appearance in selected patients with chronic laryngitis after eight weeks of therapy with rabeprazole. Med. Sci. Monit. 10(10), PI115-PI118 (2004).
77. Steward DL, Wilson KM, Kelly DH et al. Proton pump inhibitor therapy for chronic laryngo-pharyngitis: a randomized placebo-control trial. Otolaryngol. Head Neck Surg. 131(4), 342-350 (2004).
78. Suramethacul A, Isipradit P, Saengpanich S, Gonlachanvit S. Effect of high dose PPI (rabeprazole) on laryngopharyngeal reflux disease: a prospective, double blind, randomized controlled study: Acta of the 108th AGA scientific meeting, Abstract 915. Gastroenterology 132(4 Suppl. 2), A140 (2007).
79. Sone M, Yamamuro Y, Hayashi H, Yanagi E, Niwa Y, Nakashima T. Prediction of gastroesophageal reflux in otitis media with effusion in adults. Acta Oto-Laryngologica 127, 470-473 (2007).
80. Sone M, Yamamuro Y, Hayashi H, Niwa Y, Nakashima T. Otitis media in adults as a symptom of gastroesophageal reflux. Otolaryngol. Head Neck Surg. 136, 19-22 (2007).
81. Pawar S, Lim HJ, Gill M et al. Treatment of posmasal drip with proton pump inhibitors: a prospective, randomized, placebo controlled study. Am. J. Rhinol. 21(6), 695-701 (2007).
82. Morocutti A, Merrouche M, Bjaaland T, Humphries T, Mignon M. An open-label study of rabeprazole in patients with Zollinger-Ellison syndrome or idiopathic gastric acid hypersecretion. Aliment. Pharmacol. Ther. 24(10), 1439-1444 (2006).
83. Giannini EG, Bilardi C, Dulbecco P et al. Can Helicobacter pylori eradication regimens be shortened in clinical practice? An open-label, randomized, pilot study of 4 and 7-day triple therapy with rabeprazule, high-dose levofloxacin, and tinidazole. J. Clin. Gastroenterol. 40(6), 515-520 (2006).
84. Padol S, Yuan Y, Thabane M, Padol IT, Hunt RH. The effect of CYP2C19 polymorphisms on H. pylori eradication rate in dual and triple first-line PPI therapies: a meta-analysis. Am. J. Gastroenterol. 101(7), 1467-1475 (2006).
85. Shirai N, Sugimoto M, Kodaira C et al. Dual therapy with high doses of rabeprazole and amoxicillin versus triple therapy with rabeprazole, amoxicillin, and metronidazole as a rescue regimen for Helicobacter pylori infection after the standard triple therapy. Eur. J. Clin. Pharmacol. 63(8), 743-749 (2007).
86. Kawai T, Kawakami K, Mikinori K et al. Efficacy of low-dose proton pump inhibitor (PPI) in the eradication of Helicobacter pylori following combination PPI/AC therapy in Japan. Hepatogastroenterology 54(74), 649-654 (2007).
87. Choi HS, Park DI, Hwang SJ et al. Double-dose, new-generation proton pump inhibitors do not improve Helicobacter pylori eradication rate. Helicobacter 12(6),
88. Wu IC, Wu DC, Hsu PI et al. Rabeptazole-versus esomeprazole-based eradication regimens for H. pylori infection. Helicobacter 12(6), 633-637 (2007).
89. Ji S, Kim HS, Kim JW et al. Comparison of the efficacy, of rabeprazole 10 mg and omeprazole 20 mg for the healing rapidity of peptic ulcer diseases. J. Gastroenterol. Hepatol. 21(9), 1381-1387 (2006).
90. Ando T, Ishikawa T, Kokura S, Naito Y, Yoshida N, Yoshikawa T. Endoscopic analysis of gastric ulcer after one week's treatment with omeprazole and rabeprazole in relation to CYP2C19 genotype. Dig. Dis. Sci. 53(4), 933-937 (2007).
91. Kim JI, Cheung DY, Cho SH et al. Oral proton pump inhibitors are as effective as endoscopic treatment for bleeding peptic ulcer: a prospective, randomized, controlled trial. Dig. Dis. Sci. 52(12), 3371-3376 (2007).
92. Leontiadis GI, Sharma VK, Howden CW. Proton pump inhibitor treatment for acute peptic ulcer bleeding. Cochrane Database Syst. Rev. 1, CD002094 (2006).
93. Irani S, Krevsky B, Desipio J, Kim-Jaffe J, Maqbool S, Fisher RS. Rapid protection of the gastroduodenal mucosa against aspirin-induced damage by rabeprazole. Aliment. Pharmacol. Ther. 27(6), 498-503 (2008).
94. Jaworski T, Sarosiek I, Sostarich S et al. Restorative impact of rabeprazole on gastric mucus and mucin production impairment during naproxen administration: its potential clinical significance. Dig. Dis. Sci. 50(2), 357-365 (2005).
95. Salgueiro E, Rubio T, Hidalgo A, Manso G. Safety profile of proton pump inhibitors according to the spontaneous reports of suspected adverse reactions. Int. J. Clin. Pharmacol. Ther. 44(11), 548-556 (2006).
96. Clark DW, Strandell J. Myopathy including polymyositis: a likely class adverse effect of proton pump inhibitors? Eur. J. Clin. Pharmacol. 62(6), 473-479 (2006).
97. Sanaka M, Anjiki H, Yamamoto T, Kuyama Y. Rabeprazole delays gastric emptying of a nutrient liquid. J. Gastroenterol. Hepatol. 22(11), 1806-1809 (2007).
98. Takahashi Y, Amano Y, Yuki T et al. Influence of acid suppressants on gastric emptying: cross-over analysis in healthy volunteers. J. Gastroenterol. Hepatol. 21(11), 1664-1668 (2006).
99. Grudell AB, Camilleri M, Burton DD, Stephens DA. Effect of a proton pump inhibitor on postprandial gastric volume, emptying and symptoms in healthy human subjects: a pilot study. Aliment. Pharmacol. Ther. 24(7), 1037-1043 (2006).
100. Gralnek IM, Dulai GS, Fennerty BM, Spiegel BMR. Esomeprazole versus other proton pump inhibitors in erosive esophagitis: a meta-analysis of randomized clinical trials. Clin. Gastroenterol. Hepatol. 4, 1452-1458 (2006).
101. Edwards SJ, Lind T, Lundell L. Systematic review: proton pump inhibitors (PPIs) for the healing of reflux oesophagitis - a comparison of esomeprazole with other PPIs. Aliment. Pharmacol. Ther. 24, 743-750 (2006).
102. Hunt RH, Armstrong D, James C et al. Effect on intragastric pH of a PPI with a prolonged plasma half-life: comparison between tenatoprazole and esomeprazole on the duration of acid suppression in healthy male volunteers. Am. J. Gastroenterol. 100(9), 1949-1956 (2005).
103. Pai V, Pai N. Randomized, double-blind, comparative study of dexrabeprazole 10 mg versus rabeprazole 20 mg in the treatment of gastroesophageal reflux disease. World J. Gastroenterol. 13(30), 4100-4102 (2007).
104. Pai V, Pai N. Recent developments: chiral switch in PPI therapy: S-pantoprazole. Br. Med. J. 22, 112 (2006).